Skye Bioscience Has Started Screening Patients For Phase 2 Trial (Cbeyond) Of Nimacimab, A Negative Allosteric Modulating Antibody As Weight Loss Therapeutic In Obese Patients, Interim Data Is Expected In Q2 Of 2025 And Final Data In Q4 Of 2025
Portfolio Pulse from Benzinga Newsdesk
Skye Bioscience has initiated patient screening for a Phase 2 trial of Nimacimab, a weight loss therapeutic for obese patients. Interim data is expected in Q2 2025, with final results in Q4 2025.
August 22, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Skye Bioscience has started a Phase 2 trial for Nimacimab, targeting weight loss in obese patients. This development could impact the company's stock as it progresses through clinical trials, with interim data expected in Q2 2025.
The initiation of a Phase 2 trial is a significant step in drug development, potentially increasing investor interest and stock value. The anticipation of interim and final data could lead to speculative trading.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100